Barbara Boughton | Authors

Lower Dose Chemotherapy Plus Radiation Offers Favorable Prognosis in Hodgkin’s Lymphoma Patients

December 05, 2010

Patients with early-stage Hodgkin’s lymphoma and a favorable prognosis can be treated with less intensive chemotherapy and radiotherapy regimens without affecting outcomes. This is the first study to show that less intensive therapy can be used without sacrificing benefits, according to lead author Andreas Engert, MD, and colleagues.

Survey reveals the general public knows little about lymphoma

November 23, 2010

The saying that “knowledge is power” holds especially true when it comes to a lymphoma diagnosis, and there are best practices for clinicians who want to fully educate their patients. Presentations at ASH 2010 offer data and advice on how to approach&#151and improve&#151education efforts among clinicians and patients.

Survivors of Hodgkin's lymphoma undergo multiple followup CT scans without deriving benefit

October 20, 2010

Canadian researchers also find that patients are not having recommended cancer screening studies done on a regular basis.

Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma

September 02, 2010

Combined with first-line chemotherapy, intravenous delivery therapy also confers a survival benefit over oral bisphosphonates. Gareth J. Morgan, MD, PhD, lead investigator of the Medical Research Council Myeloma IX study, will share additional trial results at ASH 2010.

From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time

August 10, 2010

Eighteen-month follow up supports lower-dose nilotinib as the new standard of care for newly diagnosed chronic myeloid leukemia. The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+CML Patients) enrolled 846 patients at 217 sites in 35 countries. Timothy P. Hughes, MD, MBBS, will present an update to the ENESTnd trial at ASH 2010.

Endometrial cancer patients don’t implement lifestyle changes to reduce comorbidities

July 13, 2010

Physicians must engage and educate patients about significant risk for cardiovascular disease.

Cytokine disruption study sheds light on increased risk for non-Hodgkin’s lymphoma in AIDS patients

July 13, 2010

HIV’s disruption of immune system function may cause the immune system cells themselves to become cancerous, NCI researchers have concluded. If so, this might explain why patients with AIDS are 100 times more likely to be diagnosed with non-Hodgkin’s lymphoma than the general population.

Prostate brachytherapy: Guidelines assure procedural success and safeguard patients

April 14, 2010

Mismanaged therapy at one institution has dealt a blow to the field, but practitioners explain why the technique remains worthwhile.

Biomarkers signal true progress in war against lung cancer

March 18, 2010

Testing for EGFR and ALK mutations reveals tumor behavior and helps tailor treatment.

Should surgery dominate as the standard of care for mesothelioma or be in reserve for a select group of pts?

November 24, 2009

Surgical intervention for mesothelioma has become widely accepted, but controversy persists: Should surgery be the standard of care or should it be offered only to select patients? According to scientific literature, surgery decreases morbidity and mortality while also improving outcomes compared with adjunctive therapy alone.